Biotech | August 14, 2021
Bharat Biotech’s first nasal vaccine gets approval for Phase 2 trials
This is the first of its kind vaccine for Covid 19 to get the go-ahead
This is the first of its kind vaccine for Covid 19 to get the go-ahead
Studies include Alpha, Beta, Gamma, Delta, Epsilon and Iota and it maintains antibodies for six months after the second dose
Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
Releasing it, Union Minister Jitendra Singh said India needs its database for Indian research and solutions.
AstraZeneca, Sinopharm and Moderna were part of the study
Five seats reserved for Wards of COVID warriors in central MBBS admission
It is designed to tackle mental health issues
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The new platform is the latest initiative under Lupin’s long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailment
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
Subscribe To Our Newsletter & Stay Updated
